The massive overhang of 25.6M shares (82% of current float) registered for resale by a controlling stockholder creates severe near-term selling pressure. The stock's $0.2944 price is already well below the $0.6261 exchange price, suggesting the Notes are deeply out-of-the-money and the forced exchange at merger close will be highly dilutive. Traders should expect continued downward pressure as the market prices in the dilution and the risk that the Merger fails, which would leave the company with a going concern and no clear path to solvency. Monitor for stockholder vote on the Merger and the Issuance Approval, which are prerequisites for the forced exchange.
Price Chart
Executive Summary
Senti Biosciences filed an S-3/A to register 25,555,024 shares of common stock for resale by selling securityholders (Celadon affiliate CPIF II-7 and NSG BioInnovation Fund), representing 82.1% of current outstanding shares. These shares are issuable upon exchange of $16.0M in Senior Secured Convertible Notes issued in a private placement. The company has a going concern warning, a pending merger with a Celadon affiliate that will divest its core business, and an accumulated deficit of $375.5M. The massive potential dilution from the resale registration and the company's precarious financial position make this filing highly bearish for existing shareholders.
Key Financial Metrics
Key Facts
- S-3/A registers 25,555,024 shares for resale, representing 82.1% of current outstanding common stock.
- Shares issuable upon exchange of $16.0M in Senior Secured Convertible Notes held by Celadon affiliate and NSG.
- Company has a going concern warning and accumulated deficit of $375.5M as of June 30, 2026.
- Pending merger with Celadon affiliate will divest substantially all of the company's existing business and pipeline.
- Lead Investor (Celadon affiliate) would beneficially own 60.0% of common stock upon exchange of its Notes.
- Company received approximately $15.5M in net proceeds from the Notes issuances; will not receive proceeds from this resale.
- Notes have an initial exchange price of $0.6261 per share; stock closed at $0.2944 on September 9, 2026.
- Pro forma net tangible book value per share after exchange would be $(0.03), with dilution of $0.65 per share to new investors.
- Company has incurred recurring losses and negative cash flows from operations.
- Celadon holds three of eight board seats and has a binding commitment to purchase $2.5M of common stock at closing of the Merger.
Financial Impact
Potential dilution of 82.1% from the 25,555,024 registered shares alone, with additional potential dilution up to 205.1% if all $40M of Notes are issued and exchanged. Pro forma net tangible book value per share would decline from $(0.53) to $(0.03) after exchange of current Notes.
Risk Factors
- Massive dilution of 82.1% from registered resale shares alone, with potential for 205% total dilution if all Notes are issued and exchanged.
- Going concern risk with accumulated deficit of $375.5M and negative cash flows; company may not maintain operations past Q4 2026.
- Pending Merger with Celadon affiliate will divest core business, leaving a shell company with minimal assets and no revenue.
- Controlling stockholder (Celadon) can sell shares without volume limitations, creating sustained selling pressure.
- Stock price ($0.2944) is significantly below the Notes' exchange price ($0.6261), indicating the Notes are deeply out-of-the-money and the forced exchange will be highly dilutive.
- Merger is subject to stockholder approval and other conditions; failure would leave the company with no viable path forward.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001193125-26-388031 |
| Document: d87527dex991.htm | 0001193125-26-388031 |
| Document: d87527dexfilingfees.htm | 0001193125-26-388031 |
| Document: d87527dex51.htm | 0001193125-26-388031 |
| Document: 0001193125-26-388031-index-headers.html | 0001193125-26-388031 |
| Document: 0001193125-26-388031-index.html | 0001193125-26-388031 |
| Document: 0001193125-26-388031.txt | 0001193125-26-388031 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.1720 | awaiting T+5 | — | $0.1660 (+3.49%) |
Oct 13, 2026 13d ago | DEFA14A | $0.2408 $0.2175 | ▼ −9.68% | ▼ −10.13% | $0.1660 (−31.06%) |
Oct 13, 2026 13d ago | 8-K | $0.2408 $0.2175 | ▲ +9.68% | ▲ +10.13% | $0.1660 (+31.06%) |
Sep 25, 2026 4w ago | EFFECT | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1660 (+49.59%) |
Sep 24, 2026 4w ago | DEFM14A | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1660 (+49.59%) |
Sep 22, 2026 5w ago | S-3/A | $0.3156 $0.3075 | ▲ +2.57% | ▲ +1.38% | $0.1660 (+47.40%) |
Sep 10, 2026 6w ago | S-3/A | $0.3060 $0.3200 | ▼ −4.58% | ▼ −4.80% | $0.1660 (+45.75%) |
Sep 4, 2026 7w ago | DEFA14A | $0.3326 $0.3021 | ▼ −9.17% | ▼ −7.96% | $0.1660 (−50.09%) |
Sep 4, 2026 7w ago | 8-K | $0.3326 $0.3021 | ▲ +9.17% | ▲ +7.96% | $0.1660 (+50.09%) |
Aug 20, 2026 9w ago | 8-K | $0.3886 $0.3770 | ▲ +2.99% | ▲ +3.46% | $0.1660 (+57.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers